After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking off 2025 with a return to the dealmaking table. Under a new licensing pact, ...
The biotech industry has certainly hit the ground running in 2026. In its first edition of the year, the biotech bi-weekly highlights new products that can visualize multimodal biological data at ...
Biotech insiders tout antibody-drug conjugates as the next big thing in cancer treatment, with firms urged to pursue global strategies Antibody-drug conjugates (ADC), a fast-growing next-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results